Clinical Trial

HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the efficacy and safety and the best effective dose of HuHuangLianzonggan capsule in subjects with nonalcoholic steatohepatitis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-11-20; most recent amendment 2024-08-28.
Status change: Not Yet Recruiting → Recruiting 2023-08-07
Trial Details
NCT Number NCT05632861
Lead Sponsor Tasly Pharmaceutical Group Co., Ltd
Conditions NASH
Enrollment 76 participants
Start Date 2023-02-21
Primary Completion 2024-12-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-29